Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 2Phase 3 1

Status

Recruiting 3

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Squamous Cell Carcinoma of Head and Neck 9Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Oropharyngeal Neoplasms 7Mouth Neoplasms 7Laryngeal Neoplasms 7Carcinoma 6Hypopharyngeal Neoplasms 5Urinary Bladder Neoplasms 4Pancreatic Neoplasms 3Nasopharyngeal Carcinoma 3Vulvar Neoplasms 2Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Paranasal Sinus Neoplasms 2Lymphoid Interstitial Pneumonia 2Cholangiocarcinoma 2Anus Neoplasms 2Adenocarcinoma of Lung 2Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Stomatitis 1Stomach Neoplasms 1Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7 1Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 1Sinonasal undifferentiated carcinoma 1Sinonasal Squamous Cell Carcinoma 1Sertoli-Leydig Cell Tumor 1

Interventions

Cisplatin 51Gemcitabine 26toripalimab 20Radiotherapy, Intensity-Modulated 19Fluorouracil 16Capecitabine 16camrelizumab 15Docetaxel 14nimotuzumab 12Radiotherapy 10Drug Therapy 10apatinib 9Nivolumab 9sintilimab 8endostar protein 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Immune Checkpoint Inhibitors 7tislelizumab 6spartalizumab 6Chemoradiotherapy 6Cetuximab 6Bevacizumab 6pembrolizumab 5nedaplatin 5S 1 (combination) 5Radiation 5Paclitaxel 5Endostatins 5anlotinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Nasopharyngeal Carcinoma × 1,2-diaminocyclohexaneplatinum II citrate × Clear all
NCT06029270 2026-06-03

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
156 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT06064097 2026-06-03

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

National Cancer Institute (NCI)

Phase 2 Recruiting
50 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT06532279 2026-05-04

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NRG Oncology

Phase 2 Recruiting
98 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Stomatitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡